ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
ScripGilead Sciences’ TROP2-directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) has a strong chance of cornering most of the market for first-line advanced or metastatic triple-negative
Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
ScripSummit Therapeutics and Akeso delivered mixed results from the first multi-regional Phase III study of ivonescimab, the companies’ PD-1/VEGF-targeting immunotherapy, in non-small cell lung cancer (NSC